摘要
This retrospective single centre report of 36 patients with resectable pancreatic cancer who had neoadjuvant systemic chemotherapy,found that only 25(69%)of patients could undergo resection with a median overall survival of 34.4 months(1).They concluded that a short course of neoadjuvant chemotherapy without chemoradiation may improve patient selection prior to surgical resection(1).Whilst the notion that effective neoadjuvant therapy does not require chemoradiation is interesting this study demonstrates the weaknesses of retrospective studies.Progress in the treatment of pancreatic cancer has only taken place through well designed prospective randomized controlled trials.
